Employee Benefit Plans (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of share-based compensation, stock options, activity

The following table summarizes the Company’s stock option activity and related information as of and for the nine months ended September 30, 2018 (in millions, except for per share amounts and years):



	Outstanding Options
	Number of Shares		Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value
Balance as of December 31, 2017	0.9		$	34.41
Exercised	(0.1	)	4.20
Expired/Canceled	(0.7	)	40.34
Balance as of September 30, 2018	0.1		$	19.80	1.9	$	1.2

As of September 30, 2018:
Vested and expected-to-vest options	0.1		$	19.80	1.9	$	1.2
Exercisable options	0.1		$	22.24	1.0	$	0.8

Schedule of nonvested share activity

The Company’s RSU and PSA activity and related information as of and for the nine months ended September 30, 2018 were as follows (in millions, except per share amounts and years):



	Outstanding RSUs and PSAs⁽⁴⁾
	Number of Shares		Weighted Average Grant-Date Fair Value per Share		Weighted Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value
Balance as of December 31, 2017	19.5		$	25.39
RSUs granted ⁽¹⁾⁽³⁾	6.5		25.36
PSAs granted⁽²⁾⁽³⁾	0.7		24.43
RSUs vested	(5.4	)	25.43
PSAs vested	(1.1	)	24.14
RSUs canceled	(1.5	)	26.34
PSAs canceled	(0.7	)	24.39
Balance as of September 30, 2018	18.0		$	25.37	1.1	$	538.8

________________________________

⁽¹⁾

Includes service-based and market-based RSUs. The number of shares subject to market-based condition represents the aggregate maximum number of shares that may be issued pursuant to the award over its full term. The aggregate number of shares subject to market-based condition that would be issued if market criteria determined by the Compensation Committee of the Board are achieved at target is 0.1 million shares. Depending on achievement of such performance goals, the range of shares that could be issued under these awards is zero to 0.3 million shares.

⁽²⁾

The number of shares subject to PSAs granted represents the aggregate maximum number of shares that may be issued pursuant to the award over its full term. The aggregate number of shares subject to these PSAs that would be issued if performance goals determined by the Compensation Committee of the Board are achieved at target is 0.4 million shares. Depending on achievement of such performance goals, the range of shares that could be issued under these awards is zero to 0.7 million shares.

⁽³⁾

The grant date fair value of RSUs and PSAs were reduced by the present value of dividends expected to be paid on the underlying shares of common stock during the requisite and derived service period as these awards are not entitled to receive dividends until vested. During the nine months ended September 30, 2018, the Company declared a quarterly cash dividend of $0.18 per share of common stock on January 30, 2018, May 2, 2018, and July 26, 2018.

⁽⁴⁾

2.0 million shares of PSAs were modified during the nine months ended September 30, 2018, which relate primarily to PSAs assumed by the Company in connection with acquisitions consummated in 2016. These awards are contingent upon the achievement of certain performance milestones. Compensation cost resulting from the modifications totaled $6.3 million to be recognized over the remaining terms of the modified awards.

Summary of employee stock purchases through the ESPP

The following table summarizes employee stock purchases through the ESPP (in millions, except per share amounts):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Shares purchased	1.2		1.2		2.5		2.7
Average exercise price per share	$	22.39	$	22.79	$	22.31	$	20.83

Schedule of employee service share-based compensation, allocation of recognized period costs

Share-based compensation expense associated with stock options, RSUs, restricted stock awards ("RSAs"), PSAs, and the ESPP was recorded in the following cost and expense categories in the Condensed Consolidated Statements of Operations (in millions):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Cost of revenues - Product	$	1.5	$	1.5	$	5.1	$	3.8
Cost of revenues - Service	4.5		3.9		14.2		13.5
Research and development	28.1		18.5		101.8		67.4
Sales and marketing	12.9		13.7		40.4		45.3
General and administrative	6.2		7.4		18.7		21.1
Total	$	53.2	$	45.0	$	180.2	$	151.1

Disclosure of share-based compensation arrangements by share-based payment award

The following table summarizes share-based compensation expense by award type (in millions):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Stock options	$	0.1	$	0.2	$	0.3	$	0.5
RSUs, RSAs, and PSAs	48.2		41.0		165.8		138.9
ESPP	4.9		3.8		14.1		11.7
Total	$	53.2	$	45.0	$	180.2	$	151.1